D. Schteingart, G. Doherty, and P. Gauger, Management of patients with adrenal 382 cancer: recommendations of an international consensus conference, Endocr Relat Cancer, vol.383, issue.12, pp.667-680, 2005.

A. Berruti, E. Baudin, and H. Gelderblom, Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.23, issue.suppl 7, pp.131-138, 2012.
DOI : 10.1093/annonc/mds231

E. Baudin, S. Leboulleux, A. Ghuzlan, and A. , Therapeutic Management of Advanced Adrenocortical Carcinoma: What Do We Know in 2011?, Hormones and Cancer, vol.142, issue.1, pp.363-371, 2011.
DOI : 10.1007/s12672-011-0094-2

M. Fassnacht, M. Terzolo, and B. Allolio, Combination Chemotherapy in Advanced Adrenocortical Carcinoma, New England Journal of Medicine, vol.366, issue.23, pp.2189-2197, 2012.
DOI : 10.1056/NEJMoa1200966

A. Berruti, M. Fassnacht, and E. Baudin, Adjuvant therapy in patients with adrenocortical 393 carcinoma: a position of an international panel, J Clin Oncol Off J Am Soc Clin Oncol, vol.394, issue.28, pp.401-402, 2010.

T. Else, A. Williams, and A. Sabolch, Adjuvant therapies and patient and tumor 396 characteristics associated with survival of adult patients with adrenocortical carcinoma, J Clin, vol.397, 2014.

H. Haak, J. Hermans, and C. Van-de-velde, Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients, British Journal of Cancer, vol.69, issue.5, pp.947-951, 1994.
DOI : 10.1038/bjc.1994.183

E. Baudin, G. Pellegriti, and M. Bonnay, Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p?DDD) levels on the treatment of patients with adrenocortical carcinoma, Cancer, vol.62, issue.6, pp.1385-1392, 2001.
DOI : 10.1002/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2

P. Malandrino, A. Ghuzlan, A. Castaing, and M. , Prognostic markers of survival after 404 combined mitotane-and platinum-based chemotherapy in metastatic adrenocortical carcinoma 405 (ACC), Endocr Relat Cancer, pp.10-1677, 2010.

B. Wängberg, A. Khorram-manesh, and S. Jansson, The long-term survival in 407 adrenocortical carcinoma with active surgical management and use of monitored mitotane, 2010.

I. Hermsen, M. Fassnacht, and M. Terzolo, Plasma Concentrations of o,p???DDD, o,p???DDA, and o,p???DDE as Predictors of Tumor Response to Mitotane in Adrenocortical Carcinoma: Results of a Retrospective ENS@T Multicenter Study, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.6, pp.1844-1851, 1210.
DOI : 10.1210/jc.2010-2676

M. Ayala-ramirez, S. Jasim, and L. Feng, Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center, European Journal of Endocrinology, vol.169, issue.6, pp.891-899, 2013.
DOI : 10.1530/EJE-13-0519

H. Van-slooten, A. Moolenaar, A. Van-seters, and D. Smeenk, The treatment of adrenocortical 417 carcinoma with o,p'-DDD: prognostic implications of serum level monitoring, Eur J Cancer, p.418, 1984.

M. Rh, Studies of the pharmacology of o,p'DDD in man, J Lab Clin Med, vol.58, pp.296-304, 1961.

J. Sinsheimer, J. Guilford, L. Bobrin, and D. Schteingart, Identification of o,p'- 421 dichlorodiphenyl acetic acid as a urinary metabolite of 1-(o-chlorophenyl, p.1, 1972.

V. Reif and J. Sinsheimer, Metabolism of 1-(0-chlorophenyl)-1-(p-chlorophenyl)-2,2- 424 dichloroethane (o,p'-DDD) in rats, Drug Metab Dispos Biol Fate Chem, vol.3, pp.15-25, 1975.

D. Schteingart, Adjuvant mitotane therapy of adrenal cancer -use and controversy. N Engl 426, J Med, vol.356, pp.2415-2418, 2007.

F. Martz and J. Straw, Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p- 428 chlorophenyl)-2,2-dichloroethane (o,p,'-DDD) Correlation between adrenocorticolytic 429 activity and metabolic activation by adrenocortical mitochondria, Drug Metab Dispos Biol, vol.430, 1980.

R. Pohland and R. Counsell, In vitro and in vivo metabolism of a radioiodinated analog of 1- 432 (2-chlorophenyl)-1-(4-chlorophenyl)-2,-dichloroethane, Drug Metab Dispos Biol Fate Chem, vol.433, issue.13, pp.113-115, 1985.

F. Martz and J. Straw, The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2- 435 dichloroethane (o,p'-DDD) by dog adrenal mitochondria and metabolite covalent binding to 436 mitochondrial macromolecules: a possible mechanism for the adrenocorticolytic effect, 1977.

W. Cai, R. Benitez, and R. Counsell, Bovine adrenal cortex transformations of mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p???-DDD] and its p,p???- and m,p???-isomers, Biochemical Pharmacology, vol.49, issue.10, pp.1483-1489, 1995.
DOI : 10.1016/0006-2952(95)00028-X

W. Cai, R. Counsell, and T. Djanegara, Metabolic Activation and Binding of Mitotane in Adrenal Cortex Homogenates, Journal of Pharmaceutical Sciences, vol.84, issue.2, pp.134-138, 1995.
DOI : 10.1002/jps.2600840203

W. Cai, R. Counsell, and D. Schteingart, Adrenal proteins bound by a reactive intermediate of mitotane, Cancer Chemotherapy and Pharmacology, vol.39, issue.6, pp.537-540, 1997.
DOI : 10.1007/s002800050610

S. Hescot, A. Slama, and A. Lombès, Mitotane alters mitochondrial respiratory chain 446 activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat 447, Cancer, vol.20, pp.371-381, 2013.

E. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-247, 1990.
DOI : 10.1016/j.ejca.2008.10.026

S. Mauclère-denost, S. Leboulleux, and I. Borget, High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up, European Journal of Endocrinology, vol.166, issue.2, pp.261-268, 2012.
DOI : 10.1530/EJE-11-0557

T. Kerkhofs, E. Baudin, and M. Terzolo, Comparison of two mitotane starting dose 456 regimens in patients with advanced adrenocortical carcinoma, J Clin Endocrinol Metab, vol.457, issue.98, pp.4759-4767, 2013.

T. Lehmann, T. Wrzesi?ski, and P. Jagodzi?ski, The effect of mitotane on viability, 459 steroidogenesis and gene expression in NCI?H295R adrenocortical cells, Mol Med Rep, vol.460, issue.7, pp.893-900, 2013.

G. Poli, D. Guasti, and E. Rapizzi, Morpho-functional effects of mitotane on mitochondria 462 in human adrenocortical cancer cells, Endocr Relat Cancer, 2013.

V. Chortis, A. Taylor, and P. Schneider, Mitotane Therapy in Adrenocortical Cancer Induces CYP3A4 and Inhibits 5??-Reductase, Explaining the Need for Personalized Glucocorticoid and Androgen Replacement, The Journal of Clinical Endocrinology & Metabolism, vol.98, issue.1, pp.161-1712012, 2013.
DOI : 10.1210/jc.2012-2851

A. Takeshita, J. Igarashi-migitaka, N. Koibuchi, and Y. Takeuchi, Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor, Journal of Endocrinology, vol.216, issue.3, pp.297-305, 2013.
DOI : 10.1530/JOE-12-0297

D. Avolio, A. , D. Francia, S. Basile, and V. , Influence of the CYP2B6 polymorphism on the 470 pharmacokinetics of mitotane Management of Addison's disease in adrenalectomized 473 patients, Pharmacogenet Genomics Bull N Y Acad Med, vol.23, issue.29, pp.293-300295, 1953.

D. Schteingart, J. Sinsheimer, and R. Benitez, Structural requirements for mitotane 475 activity: development of analogs for treatment of adrenal cancer, Anticancer Res, vol.32, pp.2711-476, 2012.

V. Asp, T. Cantillana, A. Bergman, and I. Brandt, Chiral effects in adrenocorticolytic action of 478 o,p'-DDD (mitotane) in human adrenal cells, Xenobiotica Fate Foreign Compd Biol Syst, vol.479, issue.40, pp.177-183, 2010.

±. Sem, DDD concentration in cell culture medium at time zero (T0) Each 542 experiment was repeated 3 to 5 times. H295R cell uptake represents 40% of initial o,p'DDD yet 543 o,p'DDA was not recovered in the cell pellet whether H295R cells were incubated with o,p'DDD or 544 o, DDA. *P<0.05 and **P<0.01, Mann-Whitney U test